Trader Regeneron Pharmaceuticals, Inc. - REGN CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Écart | 1.64 | ||||||||
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.030779% | ||||||||
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | -0.013666% | ||||||||
Durée des frais en overnight | 22:00 (UTC) | ||||||||
Quantité minimale négociée | 1 | ||||||||
Devise | USD | ||||||||
Marge | 20% | ||||||||
Bourse | United States of America | ||||||||
Commission sur la négociation | 0% |
*Information provided by Capital.com
Regeneron Pharmaceuticals Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Fermeture précédente* | 767.06 |
Ouvert* | 762.53 |
Variation sur 1 an* | 22.61% |
Fourchette du jour* | 748 - 762.89 |
Fourchette sur 52 semaines | 538.01-800.48 |
Volume moyen (10 jours) | 780.09K |
Volume moyen (3 mois) | 13.47M |
Capitalisation boursière | 83.85B |
Ratio C/B | 20.14 |
Actions en circulation | 109.33M |
Revenu | 12.17B |
EPS | 38.24 |
Dividende (rendement en %) | N/A |
Bêta | 0.21 |
Prochaine date de publication des résultats | May 2, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Clôture | Change | Change (%) | Ouverture | High | Low |
---|---|---|---|---|---|---|
Feb 8, 2023 | 748.54 | -13.24 | -1.74% | 761.78 | 767.79 | 744.16 |
Feb 7, 2023 | 767.06 | 3.20 | 0.42% | 763.86 | 777.39 | 756.52 |
Feb 6, 2023 | 777.87 | -4.73 | -0.60% | 782.60 | 799.83 | 773.07 |
Feb 3, 2023 | 781.51 | 25.98 | 3.44% | 755.53 | 789.52 | 752.91 |
Feb 2, 2023 | 750.43 | 10.27 | 1.39% | 740.16 | 758.10 | 735.76 |
Feb 1, 2023 | 757.17 | 4.26 | 0.57% | 752.91 | 761.95 | 741.22 |
Jan 31, 2023 | 757.61 | 18.68 | 2.53% | 738.93 | 758.62 | 738.93 |
Jan 30, 2023 | 736.29 | -6.26 | -0.84% | 742.55 | 746.95 | 730.67 |
Jan 27, 2023 | 742.43 | 0.57 | 0.08% | 741.86 | 747.94 | 738.87 |
Jan 26, 2023 | 741.41 | 1.29 | 0.17% | 740.12 | 745.24 | 730.89 |
Jan 25, 2023 | 740.89 | 21.04 | 2.92% | 719.85 | 743.70 | 719.85 |
Jan 24, 2023 | 726.47 | -4.62 | -0.63% | 731.09 | 731.09 | 720.83 |
Jan 23, 2023 | 729.10 | 13.61 | 1.90% | 715.49 | 732.54 | 710.18 |
Jan 20, 2023 | 720.89 | 0.54 | 0.07% | 720.35 | 725.08 | 712.07 |
Jan 19, 2023 | 715.30 | -5.20 | -0.72% | 720.50 | 728.74 | 710.98 |
Jan 18, 2023 | 724.16 | 4.22 | 0.59% | 719.94 | 728.95 | 719.85 |
Jan 17, 2023 | 727.63 | 9.94 | 1.38% | 717.69 | 731.09 | 709.88 |
Jan 13, 2023 | 721.17 | 8.76 | 1.23% | 712.41 | 724.20 | 705.29 |
Jan 12, 2023 | 714.10 | 11.57 | 1.65% | 702.53 | 715.30 | 695.40 |
Jan 11, 2023 | 709.10 | 10.75 | 1.54% | 698.35 | 711.03 | 688.80 |
Regeneron Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annuel
- Trimestriel
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Revenu total | 4860.43 | 5872.23 | 6710.8 | 7863.4 | 8497.1 | 16071.7 |
Revenu | 4860.43 | 5872.23 | 6710.8 | 7863.4 | 8497.1 | 16071.7 |
Coût des recettes, total | 299.694 | 397.061 | 434.1 | 782.2 | 1119.9 | 2437.5 |
Résultat brut | 4560.73 | 5475.17 | 6276.7 | 7081.2 | 7377.2 | 13634.2 |
Total des frais d'exploitation | 3529.69 | 3792.64 | 4176.4 | 5653.6 | 4920.5 | 7124.9 |
Total des frais de vente/Généraux/Admin | 1177.7 | 1320.43 | 1556.2 | 1834.8 | 1346 | 1824.9 |
Recherche et développement | 2052.29 | 2075.14 | 2186.1 | 3036.6 | 2735 | 2908.1 |
Produits d'exploitation | 1330.74 | 2079.59 | 2534.4 | 2209.8 | 3576.6 | 8946.8 |
Produits (charges) d'intérêts, nets Hors exploitation | -7.195 | -25.119 | 13.7 | 88.1 | 139.1 | 328.8 |
Autres, nets | 6.269 | 24.039 | 5.4 | 131.2 | 94.7 | 50.2 |
Résultat net avant impôts | 1329.81 | 2078.51 | 2553.5 | 2429.1 | 3810.4 | 9325.8 |
Résultat net après impôts | 895.522 | 1524.71 | 2376.4 | 2115.8 | 3513.2 | 8075.3 |
Résultat net avant éléments extra | 895.522 | 1524.71 | 2376.4 | 2115.8 | 3513.2 | 8075.3 |
Résultat net | 895.522 | 1198.51 | 2444.4 | 2115.8 | 3513.2 | 8075.3 |
Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | 895.522 | 1524.71 | 2376.4 | 2115.8 | 3513.2 | 8075.3 |
Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | 895.522 | 1198.51 | 2444.4 | 2115.8 | 3513.2 | 8075.3 |
Ajustement pour dilution | 0.5039 | 0 | ||||
Résultat net dilué | 896.026 | 1198.51 | 2444.4 | 2115.8 | 3513.2 | 8075.3 |
Moyenne pondérée des actions diluées | 116.367 | 115.954 | 114.8 | 114.6 | 115.1 | 112.2 |
BPA dilué hors éléments extraordinaires | 7.7 | 13.1493 | 20.7003 | 18.4625 | 30.523 | 71.9724 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||||
BPA dilué normalisé | 7.7 | 13.1493 | 20.7003 | 18.4625 | 30.523 | 71.9724 |
Total des éléments extraordinaires | -326.2 | 68 | ||||
Other Operating Expenses, Total | -280.4 | -45.6 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Revenu total | 2528.7 | 5138.5 | 3452.8 | 4951.7 | 2965.1 |
Revenu | 2528.7 | 5138.5 | 3452.8 | 4951.7 | 2965.1 |
Coût des recettes, total | 308 | 693.7 | 453.2 | 982.6 | 404.9 |
Résultat brut | 2220.7 | 4444.8 | 2999.6 | 3969.1 | 2560.2 |
Total des frais d'exploitation | 1416 | 1791.3 | 1605.6 | 2312 | 1706.6 |
Total des frais de vente/Généraux/Admin | 405.6 | 414.7 | 445 | 559.6 | 450 |
Recherche et développement | 742.9 | 714.2 | 665.4 | 785.6 | 843.8 |
Other Operating Expenses, Total | -40.5 | -31.3 | 42 | -15.8 | -20.2 |
Produits d'exploitation | 1112.7 | 3347.2 | 1847.2 | 2639.7 | 1258.5 |
Produits (charges) d'intérêts, nets Hors exploitation | 129.3 | 394.6 | -43.3 | -151.8 | -224.8 |
Autres, nets | 11 | 11 | 12.7 | 15.5 | 27.4 |
Résultat net avant impôts | 1253 | 3752.8 | 1816.6 | 2503.4 | 1061.1 |
Résultat net après impôts | 1115.2 | 3098.9 | 1632.2 | 2229 | 973.5 |
Résultat net avant éléments extra | 1115.2 | 3098.9 | 1632.2 | 2229 | 973.5 |
Résultat net | 1115.2 | 3098.9 | 1632.2 | 2229 | 973.5 |
Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | 1115.2 | 3098.9 | 1632.2 | 2229 | 973.5 |
Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | 1115.2 | 3098.9 | 1632.2 | 2229 | 973.5 |
Résultat net dilué | 1115.2 | 3098.9 | 1632.2 | 2229 | 973.5 |
Moyenne pondérée des actions diluées | 110.5 | 110.8 | 113.9 | 113.4 | 113.1 |
BPA dilué hors éléments extraordinaires | 10.0923 | 27.9684 | 14.3301 | 19.6561 | 8.60743 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
BPA dilué normalisé | 10.0923 | 27.9684 | 14.3301 | 19.6561 | 8.85588 |
Charges (revenus) inhabituelles | 28.1 |
- Annuel
- Trimestriel
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total de l'actif à court terme | 3180.19 | 4335.03 | 6447.6 | 7689.1 | 9779.1 | 14014.9 |
Espèces et placements à court terme | 1038.68 | 1409.58 | 2809.9 | 3214.3 | 3587 | 5694.7 |
Trésorerie et équivalents | 535.203 | 812.733 | 1467.7 | 1617.8 | 2193.7 | 2885.6 |
Investissements à court terme | 503.481 | 596.847 | 1342.2 | 1596.5 | 1393.3 | 2809.1 |
Total des créances, nettes | 1611.62 | 1974.34 | 2243.2 | 2672.2 | 4114.7 | 6036.5 |
Accounts Receivable - Trade, Net | 1611.62 | 1974.34 | 2243.2 | 2672.2 | 4114.7 | 6036.5 |
Total Inventory | 307.922 | 513.878 | 822.3 | 1014.6 | 1485.7 | 1502.8 |
Prepaid Expenses | 130.528 | 224.972 | 243.3 | 387.1 | 160.8 | 332.4 |
Other Current Assets, Total | 91.434 | 212.26 | 328.9 | 400.9 | 430.9 | 448.5 |
Total Assets | 6973.47 | 8764.29 | 11734.5 | 14805.2 | 17163.3 | 25434.8 |
Property/Plant/Equipment, Total - Net | 2083.42 | 2358.6 | 2575.8 | 2890.4 | 3221.6 | 3482.2 |
Property/Plant/Equipment, Total - Gross | 2508.93 | 2924.9 | 3304.5 | 3812.8 | 4352.7 | 4880.3 |
Accumulated Depreciation, Total | -425.504 | -566.294 | -728.7 | -922.4 | -1131.1 | -1398.1 |
Long Term Investments | 864.26 | 1486.49 | 1800.5 | 3312.4 | 3194.8 | 6878 |
Other Long Term Assets, Total | 845.597 | 584.157 | 910.6 | 913.3 | 967.8 | 1059.7 |
Total Current Liabilities | 1241.49 | 1135.48 | 1442.8 | 2096.6 | 2697.4 | 3932.5 |
Accounts Payable | 134.984 | 178.183 | 218.2 | 418.1 | 475.5 | 564 |
Accrued Expenses | 508.336 | 636.668 | 751.3 | 1037.4 | 1502.3 | 1880.5 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 127.274 | 0 | 719.7 | |||
Other Current Liabilities, Total | 470.901 | 320.632 | 473.3 | 641.1 | 719.6 | 768.3 |
Total Liabilities | 2524.22 | 2620.21 | 2977.2 | 3715.5 | 6138 | 6666 |
Total Long Term Debt | 351.569 | 703.453 | 708.5 | 713.9 | 2695.7 | 1980 |
Capital Lease Obligations | 351.569 | 703.453 | 708.5 | 713.9 | 717.2 | 0 |
Other Liabilities, Total | 931.157 | 781.272 | 825.9 | 905 | 744.9 | 753.5 |
Total Equity | 4449.25 | 6144.08 | 8757.3 | 11089.7 | 11025.3 | 18768.8 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.11 | 0.112 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-In Capital | 3029.99 | 3512.83 | 3911.6 | 4428.6 | 6716.2 | 8087.5 |
Retained Earnings (Accumulated Deficit) | 1748.22 | 2946.73 | 5254.3 | 7379.8 | 10893 | 18968.3 |
Treasury Stock - Common | -316.24 | -316.24 | -396.4 | -739.9 | -6613.3 | -8260.9 |
Other Equity, Total | -12.84 | 0.64 | -12.3 | 21.1 | 29.3 | -26.2 |
Total Liabilities & Shareholders’ Equity | 6973.47 | 8764.29 | 11734.5 | 14805.2 | 17163.3 | 25434.8 |
Total Common Shares Outstanding | 106.008 | 107.625 | 109.006 | 110.277 | 106.951 | 108.675 |
Long Term Debt | 1978.5 | 1980 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total de l'actif à court terme | 10055.1 | 13337.6 | 13775.4 | 14014.9 | 14306 |
Espèces et placements à court terme | 3503.8 | 3910.8 | 5787.6 | 5694.7 | 7050.6 |
Trésorerie et équivalents | 1437.9 | 2072.2 | 3432.4 | 2885.6 | 3345.7 |
Investissements à court terme | 2065.9 | 1838.6 | 2355.2 | 2809.1 | 3704.9 |
Total des créances, nettes | 4173 | 6998.6 | 5452 | 6036.5 | 4839 |
Accounts Receivable - Trade, Net | 4173 | 6998.6 | 5452 | 6036.5 | 4839 |
Total Inventory | 1665.3 | 1448.9 | 1550.1 | 1502.8 | 1465.7 |
Prepaid Expenses | 213.6 | 444.3 | 482 | 332.4 | 424.9 |
Other Current Assets, Total | 499.4 | 535 | 503.7 | 448.5 | 525.8 |
Total Assets | 17772.2 | 21485.9 | 23671.5 | 25434.8 | 26348.7 |
Property/Plant/Equipment, Total - Net | 3262.6 | 3358.5 | 3395.7 | 3482.2 | 3556.4 |
Long Term Investments | 3583.7 | 3940.3 | 5671.3 | 6878 | 7130.7 |
Other Long Term Assets, Total | 870.8 | 849.5 | 829.1 | 1059.7 | 1355.6 |
Total Current Liabilities | 3217.8 | 3732.4 | 3714.8 | 3932.5 | 3007.6 |
Accounts Payable | 542.9 | 476 | 427 | 564 | 470.3 |
Accrued Expenses | 1492.2 | 2018 | 2061 | 2206.8 | 2046 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 717.8 | 718.4 | 719 | 719.7 | 0 |
Other Current Liabilities, Total | 464.9 | 520 | 507.8 | 442 | 491.3 |
Total Liabilities | 5795.2 | 6358.6 | 6413.5 | 6666 | 6434 |
Total Long Term Debt | 1978.9 | 1979.2 | 1979.6 | 1980 | 2700.4 |
Long Term Debt | 1978.9 | 1979.2 | 1979.6 | 1980 | 1980.4 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 720 |
Other Liabilities, Total | 598.5 | 647 | 719.1 | 753.5 | 726 |
Total Equity | 11977 | 15127.3 | 17258 | 18768.8 | 19914.7 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-In Capital | 6887.8 | 7225.8 | 7919.3 | 8087.5 | 8754.1 |
Retained Earnings (Accumulated Deficit) | 12008.2 | 15107.1 | 16739.3 | 18968.3 | 19941.8 |
Treasury Stock - Common | -6935.3 | -7221.4 | -7410.2 | -8260.9 | -8611.2 |
Other Equity, Total | 16.2 | 15.7 | 9.5 | -26.2 | -170.1 |
Total Liabilities & Shareholders’ Equity | 17772.2 | 21485.9 | 23671.5 | 25434.8 | 26348.7 |
Total Common Shares Outstanding | 106.644 | 106.72 | 108.527 | 108.675 | 109.507 |
- Annuel
- Trimestriel
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Revenu net/Ligne de départ | 895.5 | 1198.51 | 2444.4 | 2115.8 | 3513.2 | 8075.3 |
Liquidités provenant des activités d'exploitation | 1485.9 | 1307.11 | 2195.1 | 2430 | 2618.1 | 7081.3 |
Liquidités provenant des activités d'exploitation | 104.7 | 145.467 | 148.2 | 210.3 | 235.9 | 286.2 |
Deferred Taxes | -360.1 | 318.809 | -140 | -130.6 | 75.6 | -147.1 |
Éléments non monétaires | 605 | 570.858 | 439.5 | 435 | 297 | 783.4 |
Cash Taxes Paid | 481.4 | 754.843 | 205.6 | 342.3 | 188.1 | 1218.4 |
Intérêts payés en espèces | 5.5 | 18.678 | 22.3 | 25 | 23.2 | 55.8 |
Variation du fonds de roulement | 240.8 | -926.533 | -697 | -200.5 | -1503.6 | -1916.5 |
Flux de trésorerie liés aux activités d'investissement | -1046.8 | -1005.18 | -1463 | -2027.8 | -70.6 | -5384.7 |
Dépenses d'investissement | -511.9 | -272.626 | -383.1 | -429.6 | -614.6 | -551.9 |
Autres éléments de flux de trésorerie d'investissement, total | -534.9 | -732.556 | -1079.9 | -1598.2 | 544 | -4832.8 |
Flux de trésorerie provenant des activités de financement | -700.5 | -24.4 | -77.1 | -252.1 | -1970.5 | -1005.8 |
Éléments de flux de trésorerie de financement | -786.6 | -301.688 | -187.2 | -188 | -680.8 | -1032.7 |
Émission (remboursement) d'actions, nette | 126.7 | 240.213 | 110.1 | -64.1 | -3271.6 | 26.9 |
Émission (remboursement) de la dette, nette | -40.6 | 37.075 | 0 | 1981.9 | 0 | |
Variation nette de la trésorerie | -261.4 | 277.53 | 655 | 150.1 | 577 | 690.8 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1115.2 | 4214.1 | 5846.3 | 8075.3 | 973.5 |
Cash From Operating Activities | 668.5 | 1295.2 | 4708.8 | 7081.3 | 2101.7 |
Cash From Operating Activities | 67.4 | 138.5 | 211.7 | 286.2 | 74.3 |
Deferred Taxes | 10.1 | 51.8 | 58.8 | -147.1 | -225 |
Non-Cash Items | 15.2 | -84.9 | 153.1 | 783.4 | 455.7 |
Changes in Working Capital | -539.4 | -3024.3 | -1561.1 | -1916.5 | 823.2 |
Cash From Investing Activities | -1059 | -933.2 | -3372 | -5384.7 | -1705.3 |
Capital Expenditures | -115.3 | -263.8 | -397 | -551.9 | -141.8 |
Other Investing Cash Flow Items, Total | -943.7 | -669.4 | -2975 | -4832.8 | -1563.5 |
Cash From Financing Activities | -366.4 | -484.6 | -99.2 | -1005.8 | 64.7 |
Financing Cash Flow Items | -154.5 | -180.7 | -450.3 | -1032.7 | -98.8 |
Issuance (Retirement) of Stock, Net | -211.9 | -303.9 | 351.1 | 26.9 | 163.5 |
Net Change in Cash | -756.9 | -122.6 | 1237.6 | 690.8 | 461.1 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 |
Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 9.6646 | 10390144 | 625604 | 2022-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.9963 | 8596620 | 75947 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.9244 | 6369128 | -22691 | 2022-09-30 | LOW |
Capital World Investors | Investment Advisor | 5.7909 | 6225599 | -9012 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.699 | 5051759 | -78876 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 4.1405 | 4451385 | 73867 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.2727 | 2443289 | 60342 | 2022-09-30 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 2.1268 | 2286509 | 21175 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0837 | 2240113 | 26009 | 2022-09-30 | LOW |
Capital International Investors | Investment Advisor | 1.6437 | 1767136 | -24799 | 2022-09-30 | LOW |
Loomis, Sayles & Company, L.P. | Investment Advisor/Hedge Fund | 1.5967 | 1716617 | -48171 | 2022-09-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 1.499 | 1611534 | -82774 | 2022-09-30 | LOW |
Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.2895 | 1386332 | -42182 | 2023-01-31 | LOW |
Yancopoulos (George D) | Individual Investor | 1.1527 | 1239194 | -79973 | 2022-04-12 | LOW |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.0958 | 1178071 | 1345 | 2022-09-30 | LOW |
Putnam Investment Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0268 | 1103833 | -7670 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.8973 | 964691 | -15695 | 2021-12-31 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.8199 | 881403 | -1177 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.812 | 872985 | -10302 | 2022-09-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7325 | 787491 | -15714 | 2022-09-30 | LOW |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com GroupTradeurs
Clients actifs par mois
Volume d'investissement par mois
Retrait par mois
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Regeneron Company profile
À propos de Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. est une société de biotechnologie intégrée qui découvre, invente, développe, fabrique et commercialise des médicaments pour des maladies graves. Ses médicaments commercialisés et ses produits candidats en développement sont conçus pour aider les patients atteints de maladies oculaires, de maladies allergiques et inflammatoires, de cancer, de maladies cardiovasculaires et métaboliques, de douleurs, de troubles hématologiques, de maladies infectieuses et de maladies rares. Les produits commercialisés de la Société comprennent EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution pour injection sous-cutanée, Evkeeza (evinacumab) Injection, Inmazeb ( atoltivimab, maftivimab et odesivimab-ebgn) injectable, ARCALYST (rilonacept) injectable pour usage sous-cutané et ZALTRAP (ziv-aflibercept) injectable pour perfusion intraveineuse. Ses produits candidats en développement clinique comprennent REGN4018, REGN5668 et Fasinumab, entre autres.
- IndustrieBiotechnology / Medical Research
- Adresse777 Old Saw Mill River Rd, TARRYTOWN, NY, United States (USA)
- Employés10368
- CEOP. Roy Vagelos
Industry: | Bio Therapeutic Drugs |
777 Old Saw Mill River Road
TARRYTOWN
NEW YORK 10591
US
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 500 000 traders du monde entier qui ont choisi de trader avec Capital.com